Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for anxiety and depression, according to research presented at European Heart Rhythm Association (EHRA) 2021 conference. ICD depression
News | EP Lab | April 26, 2021
April 26, 2021 — Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for...
WEBINAR: 3-D Multi-planar Imaging to Enhance Ultrasound Guidance of Interventional Cardiac Procedures using Philips Technology.
Sponsored Content | Webinar | Structural Heart | April 26, 2021
This on-demand webinar teaches viewers how new multi-planar imaging techniques such as Cardiac MultiVue and TrueVue...
Racism and heart disease. This study looks at heart failure patients and the impact of socioeconomic disparities associate with epigenetics. The study looks to overcome preconcieved ideas about race in cardiac studies by looking at underlaying causes for the disease. Image courtesy of the American Journal of Physiology

Image courtesy of the American Journal of Physiology.

News | Heart Failure | April 26, 2021
April 26, 2021 – Cardiovascular diseases are the leading cause of death in the United States. Heart failure...
Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a structural heart procedure at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a structural heart procedure at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell
 

Feature | Structural Heart | April 22, 2021
The resounding success of transcatheter aortic valve replacement (TAVR) has led the creation of hundreds of structural...
The FDA’s market clearance occurred once the agency reviewed EnsiteVascular’s Section 510(k) premarket notification of intent to market the SiteSeal SV device and determined it is substantially equivalent for the indication for use stated: brachial artery closure. Previously, EnsiteVascular received FDA market clearance for SiteSeal SV for radial artery closure.
News | Hemostasis Management | April 21, 2021
April 21, 2021 — EnsiteVascular announced it received its second U.S. Food and Drug Administration (FDA) market...
Transforming Interventional Cardiology with Structured Reporting using Change Healthcare's cardiovascular information system (CVIS).
Webinar | Cardiovascular Information Systems (CVIS) | April 21, 2021
The adoption of structured reporting within cardiology imaging departments is on the rise. Providers recognize the...
Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a transcatheter structural heart procedure in the hybrid lab at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a transcatheter structural heart procedure in the hybrid lab at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Blog | Structural Heart | April 21, 2021
As a medical technology journalist, a little more than a decade ago I found myself sitting in those late afternoon "...
News | April 20, 2021
April 20, 2021 – The Minneapolis Heart Institute Foundation (MHIF) announced the first publication of outcomes from the...
The reSept ASD Occluder is the first structural heart occluder with a metal-free, bioresorbable frame. The novel implant is designed to overcome the limitations of current transcatheter occluders. It is hoped the design will reduce the risk of complications associated with the long-term presence of metal in the heart and to preserve future treatment options requiring transseptal intervention.

The reSept ASD Occluder is the first occluder with a metal-free, bioresorbable frame. It is designed to overcome the limitations of current transcatheter occluders by reducing the risk of complications associated with the long-term presence of metal in the heart and to preserve future treatment options requiring transseptal intervention.

News | Structural Heart Occluders | April 20, 2021
April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational...
Former Vice President Mike Pence. Photo by Airman 1st Class Aubree Owens, 30th Space Wing Public Affairs

Photo by Airman 1st Class Aubree Owens, 30th Space Wing Public Affairs

News | EP Lab | April 19, 2021
April 19, 2021 — Former Vice President Mike Pence is recovering after having a pacemaker successfully implanted to...
Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
News | Atrial Fibrillation | April 19, 2021
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm...
The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and share to the vessel and movement.

The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and shape to the vessel and its movement.

News | Stents | April 14, 2021
April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized...
The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical AcQCross family of universal transseptal crossing devices. This is the only transseptal puncture system specifically engineered to pair and mate seamlessly with Acutus’ own suite of sheaths and with sheaths sold by other manufacturers. 
News | EP Lab | April 14, 2021
April 14, 2021 — The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical AcQCross family of universal...
CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen
Feature | Coronavirus (COVID-19) | April 13, 2021 | By Dave Fornell, Editor
(This story was updated May 7, 2021 in the last subheaded section) April 13, 2021 — The U.S. Food and Drug...
Medtronic is recalling some of its implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT-D) devices because of an unexpected and rapid decrease in battery life. The company said this is due to a short circuit and will cause some devices to produce a “Recommended Replacement Time” (first warning that the battery is low) earlier than expected. Some devices may progress from “Recommended Replacement Time” to full battery depletion within as little as one day.
Feature | EP Lab | April 12, 2021
April 12, 2021 — Medtronic is recalling some of its implantable cardioverter defibrillators (ICD) and cardiac...